Related Experiment Video
Updated: Aug 6, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Complete Response to Concurrent Triplet Therapy in Low-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Case
Takashi Fujita1, Koki Kobayashi1, Gaku Hayashi1
1Department of Urology Gifu Prefectural Tajimi Hospital Tajimi Japan.
Introduction:
Triplet therapy with androgen deprivation therapy (ADT), an androgen receptor pathway inhibitor, and docetaxel improves survival in metastatic hormone-sensitive prostate cancer (mHSPC), but its role in low-volume disease remains unclear.
Case Presentation:
A 68-year-old man presented with dysuria and a PSA increase to 34.49 ng/mL. Imaging revealed a prostate tumor extending into the bladder, right obturator lymph node metastasis, and a bone lesion. Biopsy showed Gleason score 5 + 5 prostate adenocarcinoma (cT4N1M1b low-volume mHSPC). Concurrent triplet therapy with ADT, darolutamide, and docetaxel was initiated. PSA decreased to 0.1 ng/mL within 2 months, and imaging at 4.5 months demonstrated a radiological complete response. At the latest follow-up (7 months), the PSA remained below 0.03 ng/mL without progression to CRPC.
Conclusion:
Concurrent triplet therapy may achieve complete response in selected patients with aggressive low-volume mHSPC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...